Navigation Links
New England Journal of Medicine Opinion Column Suggests Ineffective Shortcuts to Solve Obesity Challenge
Date:4/8/2009

WASHINGTON, April 8 /PRNewswire-USNewswire/ -- In response to an opinion column published today in the New England Journal of Medicine, Susan Neely, president and CEO for the American Beverage Association (ABA), issued the following statement:

"We agree that obesity is a serious and complex problem. It defies both science and common sense, however, to think singling out one product as a unique contributor to obesity will make a dent in the problem. An NIH-funded study published recently in the New England Journal of Medicine found that all calories count, regardless of the source -- reaffirming the science that balancing calories consumed from all foods and beverages with the calories burned through physical activity is what matters. And common sense is underscored by the fact that obesity rates were rising in America even though soft drink sales were declining for much of this decade.

Taxing these products won't make an ounce of difference in reducing obesity. But these taxes will inflict serious pain to hard-working families, who face higher costs at the store and the risk of losing their job all in the middle of a devastating recession.

Our industry directly supports more than 220,000 good-paying jobs with health benefits in communities large and small across the country and indirectly supports more than 700,000 additional jobs in communities.

Quite simply, the American public just doesn't buy these hapless tax schemes. Consumers see them as a pure money grab that will go to pay for budget deficits created by excessive government spending.

We witnessed this in Maine, where voters rose up to overturn a tax hike on soft drinks imposed by their governor and Legislature last fall, and in New York, where Gov. David Paterson withdrew his proposed tax hike on soda due to intense public opposition.

If we really want to tackle t
'/>"/>

SOURCE American Beverage Association
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
2. Benjamin England, Former FDA Regulatory Counsel, to Testify on FDA Import Strategic Plan Before House Appropriations Subcommittee
3. Black Caribbeans do better in America than in England
4. New England Journal of Medicine Selects ScholarOnes Manuscript Central for Online Peer Review
5. Varian Image-Guided Treatment Machines Selected for Major New Hospital on South Coast of England
6. U.S. Preventive Medicine to Expand into England with iHealth UK Ltd.
7. Jobson Medical Information LLC Acquires CenterWatch and New England IRB From Thomson Healthcare
8. Boston Scientific Comments on New England Journal of Medicine Article
9. Leading IVF Practice to Open 11th New England Location
10. Kelli Pedroia, Wife of Red Sox Dustin Pedroia, Joins Melanoma Foundation of New England to Warn About Tanning for the Prom
11. Dr. Robert Leonard First in New England to Offer Genetic Test for Male Pattern Baldness
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 3Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 4Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 5Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 2Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 3Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 4Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 5Health News:VitaminSpice Signs Agreement With Former CEO of Wal-Mart Stores Division for US Distribution 2Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 2Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 3Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 4Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 5Health News:New approach to sickle-cell disease shows promise in mice 2
Breaking Medicine Technology:Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 1SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 2SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 3SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 4SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 5SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 6African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 1African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 2African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 3African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 4Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 1Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 2